Figure 5.
Development of hematological malignancies and risk of all-cause mortality for individuals with monocytosis. (A) Cumulative incidence of hematological malignancies for older individuals with monocytosis (n = 166) vs without (n = 21 435), as derived from linkage to the Netherlands Cancer Registry. Individuals with a recorded history of hematological malignancy were excluded from this analysis. (B) Kaplan-Meier plot for OS of older individuals with monocytosis (n = 167) and 1:3 matched control subjects (n = 501), stratified according to the presence of CH. (C) Kaplan-Meier plot for OS of individuals with monocytosis, stratified according to the number of mutated genes: no CH (n = 82), 1 mutated gene (n = 64), or multiple mutated genes (n = 21). (D) Kaplan-Meier plot for OS of individuals with monocytosis (n = 167), stratified according to the presence of spliceosome mutations. The category of spliceosome mutations includes SF3B1, SRSF2, and U2AF1.

Development of hematological malignancies and risk of all-cause mortality for individuals with monocytosis. (A) Cumulative incidence of hematological malignancies for older individuals with monocytosis (n = 166) vs without (n = 21 435), as derived from linkage to the Netherlands Cancer Registry. Individuals with a recorded history of hematological malignancy were excluded from this analysis. (B) Kaplan-Meier plot for OS of older individuals with monocytosis (n = 167) and 1:3 matched control subjects (n = 501), stratified according to the presence of CH. (C) Kaplan-Meier plot for OS of individuals with monocytosis, stratified according to the number of mutated genes: no CH (n = 82), 1 mutated gene (n = 64), or multiple mutated genes (n = 21). (D) Kaplan-Meier plot for OS of individuals with monocytosis (n = 167), stratified according to the presence of spliceosome mutations. The category of spliceosome mutations includes SF3B1, SRSF2, and U2AF1.

Close Modal

or Create an Account

Close Modal
Close Modal